comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 07:53:53 - browse：1238

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Cassava reveals details — and problems — with Alzheimer's study

WSS

Just how do doctors, lawmakers, and the public define abortion?

RSV shot was 90% effective at preventing hospitalizations in kids

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Paying for Covid pills will soon shift to insurers

Precocious puberty in girls comes with mental health risks

Sen. Paul opposes bill to ban Chinese biotechs

focus

comprehensive

focus

The cancer drug shortage isn’t new — and neither are the solutions

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Diversifying clinical trials isn't enough to close racial gaps: study

George Santos makes 1st court appearance after pleading not guilty to 13 counts

WHO may add ‘noma' to its list of neglected tropical diseases

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Wildfire smoke exposes gaps in outdoor worker protections

RSV shot was 90% effective at preventing hospitalizations in kids

hotspot

Eli Lilly to pay $200M for Beam’s stake in gene

UnitedHealth quietly bought dozens of outpatient centers

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Former medical device CEO who sold dummy, plastic parts convicted of fraud

First Opinion Podcast: How to protect health care in times of war

CDC recommends rationing of RSV shot due to shortages

leisure time

Wikipedia

entertainment

Wikipedia